Community Practice Connections™: Honing Patient Management Approaches With PARP Inhibition in Ovarian Cancer: What Nurses Need to Know

Release Date: September 30, 2020
Expiration Date: September 30, 2021

Activity Overview

This online program will review current guidelines, best practices, and new data in advanced ovarian cancer with commentary from nationally renowned nurses with expertise in ovarian cancer. During their interviews, the faculty discuss common clinical challenges encountered in the community setting when treating patients with PARP inhibitors, as well as personalized therapy implementation, combination strategies, and management of associated adverse events, both in the primary and relapsed/refractory settings.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, GlaxoSmithKline, and Merck & Co.

Target Audience

This educational activity is directed toward advanced practitioners, nurses, and other health care professionals interested in the multidisciplinary treatment and management of ovarian cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Summarize safety and efficacy data pertaining to the application of current and emerging PARP inhibitors in the setting of ovarian cancer
• Formulate a plan of care to manage and mitigate the impact of adverse events associated with PARP inhibitor therapy
• Outline patient and disease factors that play a role in determining appropriate PARP inhibitor treatment strategies
• Identify effective counseling strategies to educate patients who may be candidates for PARP inhibitor therapy regarding safety and efficacy

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Paula Anastasia, RN, MN, AOCN
Gyn-Oncology Clinical Nurse Specialist
Dept of OB/GYN
UCLA Health
David Geffen School of Medicine
Los Angeles, CA

Disclosures: Paula Anastasia, RN, MN, AOCN has no relevant financial relationships with commercial interests.

Kimberly Halla, MSN, FNP-C
Arizona Oncology Associates
Phoenix, AZ

Disclosures: Speaker’s Bureau: GSK, Merck.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.